Physician profile
Robert M Scharfman
NPI 1700990801
$3,257.66
in general payments reported to CMS, 2019-2025
25 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $142 · 2021: $266 · 2022: $323 · 2023: $395 · 2024: $200 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.13 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,150.46 | 2019-2025 | Tecnis Iol |
| Allergan, INC. | $540.66 | 2019-2022 | |
| Alcon Vision LLC | $249.77 | 2021-2025 | Hydrus Microstent, Eysuvis, Rocklatan |
| Bausch & Lomb Americas INC. | $221.35 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Sun Pharmaceutical Industries INC. | $162.04 | 2019-2025 | Cequa, Xelpros |
| Abbvie INC. | $120.98 | 2023-2025 | Lumigan, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $111.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $103.63 | 2019-2023 | |
| Glaukos Corporation | $92.23 | 2019 | |
| Oyster Point Pharma, INC. | $82.91 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $68.67 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $51.41 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $51.09 | 2019-2021 | |
| Thea Pharma INC. | $45.54 | 2023 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $28.28 | 2024 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $26.58 | 2021 | |
| Shire North American Group INC | $25.85 | 2019 | |
| Aerie Pharmaceuticals, INC. | $24.16 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.32 | 2025 | Syfovre |
| Dompe US, INC. | $17.27 | 2025 | Oxervate |
| Medtronic, INC. | $15.52 | 2023 | Linq II |
| Amgen INC. | $14.18 | 2024 | Tepezza |
| Akorn, INC. | $13.28 | 2020 | |
| Eyepoint US, INC. | $11.81 | 2019 | |
| Tearlab Corp | $10.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Scharfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.